{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T02:46:27Z","timestamp":1782269187661,"version":"3.54.5"},"reference-count":20,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Due to their cytotoxic nature, anticancer drugs and radiotherapy have the potential to cause toxic adverse events. As a result, they can increase the risk of morbidity and mortality. However, there was a lack of data among cervical cancer patients in our setting. Hence, this study was aimed to assess the prevalence of adverse events among cervical cancer patients at Kenyatta National Hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study design was employed among a consecutive sample of 151 adult cervical cancer patients. The data were collected by reviewing the medical records and interviewing the patients. The data were entered and analyzed using SPSS 27.0 software. The results were presented with frequency tables and graphs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 214 adverse events (prevalence of 100%) were identified from 151 patients. The most common adverse events identified were ulcerated sores (52.8%), dysuria (7.5%), thrombocytopenia (5.6%), and loss of appetite (5.6%). The majority of the patients (80.8%) who had adverse events were on radiotherapy. As per the Naranjo causality assessment scale, the predominant (80.1%) proportion of the adverse event was a probable adverse event with a total score of 5\u20138. Besides, 15.9% of the adverse events had a possible causality. The present study also reported that 61.6% of patients with a probable adverse event were treated with radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of adverse events among cervical patients was high in our setting. The predominant proportion of the adverse event was a probable adverse event and most of them were treated with radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211068133","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T05:15:58Z","timestamp":1639545358000},"page":"326-332","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of adverse events among cervical cancer patients at Kenyatta National Hospital"],"prefix":"10.1177","volume":"29","author":[{"given":"Muthoni","family":"Kibaara","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0548","authenticated-orcid":false,"given":"Amsalu","family":"Degu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy and Health Sciences, United States International University-Africa, Nairobi, Kenya."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"bibr1-10781552211068133","unstructured":"The Global Cancer Observatory. Globacan 2020 World [Internet]. [cited 2021 May 15]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/900-world-fact-sheets.pdf (accessed 15 May 2021)."},{"key":"bibr2-10781552211068133","doi-asserted-by":"publisher","DOI":"10.3329\/jemc.v9i2.41412"},{"key":"bibr3-10781552211068133","unstructured":"The Global Cancer Observatory. Globocan 2020 Kenya [Internet]. [cited 2021 May 15]. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/404-kenya-fact-sheets.pdf"},{"key":"bibr4-10781552211068133","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14143"},{"key":"bibr5-10781552211068133","doi-asserted-by":"publisher","DOI":"10.4314\/bajopas.v10i1.93S"},{"key":"bibr6-10781552211068133","unstructured":"CDC. What Are the Risk Factors for Cervical Cancer? | CDC [Internet]. 2020 [cited 2020 Sep 23]. Available from: https:\/\/www.cdc.gov\/cancer\/cervical\/basic_info\/risk_factors.htm"},{"key":"bibr7-10781552211068133","unstructured":"National Health Service. Cervical cancer - NHS [Internet]. 2020 [cited 2020 Sep 23]. Available from: https:\/\/www.nhs.uk\/conditions\/cervical-cancer\/"},{"key":"bibr8-10781552211068133","unstructured":"National cervical cancer coalition. Cervical Cancer Overview \u2013 NCCC [Internet]. [cited 2021 May 9]. Available from: https:\/\/www.nccc-online.org\/hpvcervical-cancer\/cervical-cancer-overview\/"},{"key":"bibr9-10781552211068133","unstructured":"American Cancer Society. Cervical Cancer Treatment Options | Treatment Choices by Stage [Internet]. 2020 [cited 2020 Sep 23]. Available from: https:\/\/www.cancer.org\/cancer\/cervical-cancer\/treating\/by-stage.html#references"},{"key":"bibr10-10781552211068133","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.154014"},{"key":"bibr11-10781552211068133","first-page":"15037","volume":"20","author":"Ludovick Mushi T","year":"2019","journal-title":"Biomed J Sci Tech Res"},{"key":"bibr12-10781552211068133","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000149"},{"key":"bibr13-10781552211068133","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-017-0054-9"},{"key":"bibr14-10781552211068133","first-page":"1","volume":"2","author":"Chauhan R","year":"2016","journal-title":"Womens Heal Gynecol"},{"key":"bibr15-10781552211068133","unstructured":"Kagura Y. A study to determine the relationship between comorbidity and cervical cancer diagnosis in elderly women aged 65 years and above in Zimbabwe. University of Zimbabwe 2015."},{"key":"bibr16-10781552211068133","first-page":"67","volume":"24","author":"Gebre Y","year":"2015","journal-title":"Int J Cancer Stud Res"},{"key":"bibr17-10781552211068133","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00117-8"},{"key":"bibr18-10781552211068133","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.02.013"},{"key":"bibr19-10781552211068133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.01.048"},{"key":"bibr20-10781552211068133","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S106796"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211068133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211068133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211068133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:52Z","timestamp":1777688752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211068133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10781552211068133"],"URL":"https:\/\/doi.org\/10.1177\/10781552211068133","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]}}}